AAAAAA
Results:
1-24
|
Results: 24
Authors:
Tuxen, MK
Soletormos, G
Petersen, PH
Dombernowsky, P
Citation: Mk. Tuxen et al., Interpretation of sequential measurements of cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer, CLIN CH L M, 39(6), 2001, pp. 531-538
Authors:
Underhill, CR
Parnis, FX
Highley, MS
Ahern, J
Harper, PG
Hansen, H
Lund, B
Dombernowsky, P
Hirsch, F
Hansen, M
Carmichael, J
Williams, C
Citation: Cr. Underhill et al., Multicenter phase II study of gemcitabine in previously untreated patientswith advanced epithelial ovarian cancer, ANTI-CANC D, 12(8), 2001, pp. 647-652
Authors:
Schellens, JHM
Dombernowsky, P
Cassidy, J
Epelbaum, R
Dirix, L
Cox, EH
Wanders, J
Calabresi, F
Paridaens, R
Monfardini, S
Wolff, J
Loos, WJ
Verweij, J
Pavlidis, N
Hanauske, AR
Citation: Jhm. Schellens et al., Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9, ANTI-CANC D, 12(7), 2001, pp. 583-590
Authors:
Gianni, L
Dombernowsky, P
Sledge, G
Martin, M
Amadori, D
Arbuck, SG
Ravdin, P
Brown, M
Messina, M
Tuck, D
Weil, C
Winograd, B
Citation: L. Gianni et al., Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer, ANN ONCOL, 12(8), 2001, pp. 1067-1073
Authors:
Hirsch, FR
Osterlind, K
Jeppesen, N
Dombernowsky, P
Ingeberg, S
Sorensen, PG
Kristensen, C
Hansen, HH
Citation: Fr. Hirsch et al., Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: A prospective randomised trial of 280 consecutive patients, ANN ONCOL, 12(5), 2001, pp. 647-653
Authors:
Ryberg, M
Nielsen, D
Osterlind, K
Skovsgaard, T
Dombernowsky, P
Citation: M. Ryberg et al., Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy, ANN ONCOL, 12(1), 2001, pp. 81-87
Authors:
Tuxen, MK
Soletormos, G
Dombernowsky, P
Citation: Mk. Tuxen et al., Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy, BR J CANC, 84(10), 2001, pp. 1301-1307
Authors:
Soletormos, G
Petersen, PH
Dombernowsky, P
Citation: G. Soletormos et al., Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer, CLIN CH L M, 38(5), 2000, pp. 453-463
Authors:
Sigsgaard, T
Herrstedt, J
Christensen, P
Andersen, O
Dombernowsky, P
Citation: T. Sigsgaard et al., Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D-2 antagonist metopimazine during multiple cycles ofmoderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy, SUPP CARE C, 8(3), 2000, pp. 233-237
Authors:
Sessa, C
Wanders, J
Roelvink, M
Dombernowsky, P
Nielsen, D
Morant, R
Drings, P
Wissel, P
Hanauske, AR
Citation: C. Sessa et al., Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: A study of the EORTC Early Clinical Studies Group (ECSG), ANN ONCOL, 11(2), 2000, pp. 207-210
Authors:
Sigsgaard, T
Herrstedt, J
Handberg, J
Kjaer, M
Dombernowsky, P
Citation: T. Sigsgaard et al., Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy, J CL ONCOL, 19(7), 2000, pp. 2091-2097
Authors:
Nielsen, D
Dombernowsky, P
Larsen, SK
Hansen, OP
Skovsgaard, T
Citation: D. Nielsen et al., Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study, CANC CHEMOT, 46(6), 2000, pp. 459-466
Authors:
Rose, C
Kamby, C
Mouridsen, HT
Andersson, M
Bastholt, L
Moller, KA
Andersen, J
Munkholm, P
Dombernowsky, P
Christensen, IJ
Citation: C. Rose et al., Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer - A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone and tamoxifen plus fluoxymesterone in women above 65 years of age, BREAST CANC, 61(2), 2000, pp. 103-110
Authors:
Tuxen, MK
Soletormos, G
Rustin, GJS
Nelstrop, AE
Dombernowsky, P
Citation: Mk. Tuxen et al., Biological variation and analytical imprecision of CA 125 in patients withovarian cancer, SC J CL INV, 60(8), 2000, pp. 713-721
Authors:
Soletormos, G
Petersen, PH
Dombernowsky, P
Citation: G. Soletormos et al., Progression criteria for cancer antigen 15.3 and carcinoembryonic antigen in metastatic breast cancer compared by computer simulation of marker data, CLIN CHEM, 46(7), 2000, pp. 939-949
Authors:
Andersson, M
Kamby, C
Jensen, MB
Mouridsen, H
Ejlertsen, B
Dombernowsky, P
Rose, C
Cold, S
Overgaard, M
Andersen, J
Kjaer, M
Citation: M. Andersson et al., Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-Operative Group DBCG 82B trial, EUR J CANC, 35(12), 1999, pp. 1659-1666
Authors:
Andersson, M
Madsen, EL
Overgaard, M
Rose, C
Dombernowsky, P
Mouridsen, HT
Citation: M. Andersson et al., Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer - a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group, EUR J CANC, 35(1), 1999, pp. 39-46
Authors:
Sorensen, JB
Stenbygaard, LE
Dombernowsky, P
Hansen, HH
Citation: Jb. Sorensen et al., Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer, ANN ONCOL, 10(9), 1999, pp. 1043-1049
Authors:
Stenbygaard, LE
Sorensen, JB
Larsen, H
Dombernowsky, P
Citation: Le. Stenbygaard et al., Metastatic pattern in non-resectable non-small cell lung cancer, ACTA ONCOL, 38(8), 1999, pp. 993-998
Authors:
Tuxen, MK
Soletormos, G
Petersen, PH
Schioler, V
Dombernowsky, P
Citation: Mk. Tuxen et al., Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer, GYNECOL ONC, 74(1), 1999, pp. 12-22
Authors:
Sigsgaard, T
Herrstedt, J
Andersen, LJ
Havsteen, H
Langer, SW
Kjaerbol, AG
Lund, H
Kjaer, M
Dombernowsky, P
Citation: T. Sigsgaard et al., Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy, BR J CANC, 80(3-4), 1999, pp. 412-418
Authors:
Sorensen, JB
Bergman, B
Nielsen, AL
Krarup, M
Dombernowsky, P
Hansen, HH
Citation: Jb. Sorensen et al., Phase II study of Gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer, BR J CANC, 79(5-6), 1999, pp. 875-881
Authors:
Lassen, UN
Osterlind, K
Hirsch, FR
Bergman, B
Dombernowsky, P
Hansen, HH
Citation: Un. Lassen et al., Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression, BR J CANC, 79(3-4), 1999, pp. 515-519
Authors:
Nielsen, OS
Dombernowsky, P
Mouridsen, H
Crowther, D
Verweij, J
Buesa, J
Steward, W
Daugaard, S
van Glabbeke, M
Kirkpatrick, A
Tursz, T
Citation: Os. Nielsen et al., High-dose epirubicin is not an alternative to standard-dose doxorubicin inthe treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group, BR J CANC, 78(12), 1998, pp. 1634-1639
Risultati:
1-24
|